These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9784091)

  • 1. Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease.
    Melchiorre C; Andrisano V; Bolognesi ML; Budriesi R; Cavalli A; Cavrini V; Rosini M; Tumiatti V; Recanatini M
    J Med Chem; 1998 Oct; 41(22):4186-9. PubMed ID: 9784091
    [No Abstract]   [Full Text] [Related]  

  • 2. Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine.
    Tumiatti V; Rosini M; Bartolini M; Cavalli A; Marucci G; Andrisano V; Angeli P; Banzi R; Minarini A; Recanatini M; Melchiorre C
    J Med Chem; 2003 Mar; 46(6):954-66. PubMed ID: 12620072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer.
    Tumiatti V; Milelli A; Minarini A; Rosini M; Bolognesi ML; Micco M; Andrisano V; Bartolini M; Mancini F; Recanatini M; Cavalli A; Melchiorre C
    J Med Chem; 2008 Nov; 51(22):7308-12. PubMed ID: 18954037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
    Shao D; Zou C; Luo C; Tang X; Li Y
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4639-42. PubMed ID: 15324879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation.
    Bolognesi ML; Andrisano V; Bartolini M; Banzi R; Melchiorre C
    J Med Chem; 2005 Jan; 48(1):24-7. PubMed ID: 15633997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
    Tasso B; Catto M; Nicolotti O; Novelli F; Tonelli M; Giangreco I; Pisani L; Sparatore A; Boido V; Carotti A; Sparatore F
    Eur J Med Chem; 2011 Jun; 46(6):2170-84. PubMed ID: 21459491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
    Yu Q; Holloway HW; Utsuki T; Brossi A; Greig NH
    J Med Chem; 1999 May; 42(10):1855-61. PubMed ID: 10346939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.
    Bolognesi ML; Banzi R; Bartolini M; Cavalli A; Tarozzi A; Andrisano V; Minarini A; Rosini M; Tumiatti V; Bergamini C; Fato R; Lenaz G; Hrelia P; Cattaneo A; Recanatini M; Melchiorre C
    J Med Chem; 2007 Oct; 50(20):4882-97. PubMed ID: 17850125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel aromatic-polyamine conjugates as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase.
    Hong C; Luo W; Yao D; Su YB; Zhang X; Tian RG; Wang CJ
    Bioorg Med Chem; 2014 Jun; 22(12):3213-9. PubMed ID: 24794747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 3. Effect of replacing the inner polymethylene chain with cyclic moieties.
    Tumiatti V; Andrisano V; Banzi R; Bartolini M; Minarini A; Rosini M; Melchiorre C
    J Med Chem; 2004 Dec; 47(26):6490-8. PubMed ID: 15588084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease.
    Korabecny J; Musilek K; Holas O; Binder J; Zemek F; Marek J; Pohanka M; Opletalova V; Dohnal V; Kuca K
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6093-5. PubMed ID: 20817518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
    Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
    Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush.
    Rosini M; Simoni E; Bartolini M; Cavalli A; Ceccarini L; Pascu N; McClymont DW; Tarozzi A; Bolognesi ML; Minarini A; Tumiatti V; Andrisano V; Mellor IR; Melchiorre C
    J Med Chem; 2008 Aug; 51(15):4381-4. PubMed ID: 18605718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oxidation products of melatonin derivatives exhibit acetylcholinesterase and butyrylcholinesterase inhibitory activity.
    Siwicka A; Moleda Z; Wojtasiewicz K; Zawadzka A; Maurin JK; Panasiewicz M; Pacuszka T; Czarnocki Z
    J Pineal Res; 2008 Aug; 45(1):40-9. PubMed ID: 18284552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability.
    Dillon GP; Gaynor JM; Khan D; Carolan CG; Ryder SA; Marquez JF; Reidy S; Gilmer JF
    Bioorg Med Chem; 2010 Feb; 18(3):1045-53. PubMed ID: 20093035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemiluminescent high-throughput microassay applied to imidazo[2,1-b]thiazole derivatives as potential acetylcholinesterase and butyrylcholinesterase inhibitors.
    Andreani A; Burnelli S; Granaiola M; Guardigli M; Leoni A; Locatelli A; Morigi R; Rambaldi M; Rizzoli M; Varoli L; Roda A
    Eur J Med Chem; 2008 Mar; 43(3):657-61. PubMed ID: 17624631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
    Muñoz-Ruiz P; Rubio L; García-Palomero E; Dorronsoro I; del Monte-Millán M; Valenzuela R; Usán P; de Austria C; Bartolini M; Andrisano V; Bidon-Chanal A; Orozco M; Luque FJ; Medina M; Martínez A
    J Med Chem; 2005 Nov; 48(23):7223-33. PubMed ID: 16279781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of imperatorin analogs and their evaluation as acetylcholinesterase and butyrylcholinesterase inhibitors.
    Granica S; Kiss AK; Jarończyk M; Maurin JK; Mazurek AP; Czarnocki Z
    Arch Pharm (Weinheim); 2013 Nov; 346(11):775-82. PubMed ID: 24123207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
    Elsinghorst PW; Cieslik JS; Mohr K; Tränkle C; Gütschow M
    J Med Chem; 2007 Nov; 50(23):5685-95. PubMed ID: 17944454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation.
    Belluti F; Rampa A; Piazzi L; Bisi A; Gobbi S; Bartolini M; Andrisano V; Cavalli A; Recanatini M; Valenti P
    J Med Chem; 2005 Jun; 48(13):4444-56. PubMed ID: 15974596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.